Gene-Disorder Association · Article
Gene
VHLVon Hippel-Lindau Tumor Suppressor
×
First reported
1994
Supporting publications
79
Manually curatedApproved treatment annotated
Association Review
In brief
The association between VHL (Von Hippel-Lindau Tumor Suppressor) and Renal Cell Carcinoma is reported, with clinical genetic testing available.
Sources
1
Clinical variants
0
Symptoms
1
Compounds
9
Trials
539of 5,168 via VHL compounds
Publications
79
01
At a glance
Association overview
A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access
02
Provenance
Evidence and sources
1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access
2 source summaries
A gene summary alongside the source descriptions it was distilled from.
Request access
04
Renal Cell Carcinoma
The disorder
8 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access
05
Interventions
Therapeutics
9 compounds & drugs
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access
06
Human studies
Clinical trials
5,168 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access
79 publications
Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.
Request access
08
Provenance
References & sources
14 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access